Skip to Main Content

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

Conditions

Diseases of the Digestive System - Esophagus | Diseases of the Digestive System - Small Intestines, Large Intestines & Rectum | Diseases of the Digestive System - Stomach

Phase III

What is the purpose of this trial?

Brief Summary:

The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standarddose proton pump inhibitors (PPIs).

  • Trial with
    Ironwood Pharmaceuticals, Inc.
  • Start Date
    07/01/2019
  • End Date
    12/31/2019
Trial Image

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/24/2019
  • Study HIC
    #2000023752